Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ARID1A Gene Mutation”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Testing effectiveness (Phase 2)UnknownNCT04284202
What this trial is testing

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

Who this might be right for
NSCLC Stage IVARID1APD-1
The Affiliated Hospital of Qingdao University 30
Testing effectiveness (Phase 2)Ended earlyNCT04493619
What this trial is testing

PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

Who this might be right for
Gynecologic NeoplasmsEpithelial Ovarian Cancer
Opna Bio LLC 37
Testing effectiveness (Phase 2)Ended earlyNCT05523440
What this trial is testing

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Who this might be right for
Recurrent Endometrial CarcinomaRecurrent Ovarian CarcinomaARID1A Gene Mutation
University of Oklahoma 9
Early research (Phase 1)Ended earlyNCT05226507
What this trial is testing

Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Who this might be right for
Advanced Solid TumorOvarian CancerOvarian Clear Cell Carcinoma+5 more
Nuvectis Pharma, Inc. 45
Testing effectiveness (Phase 2)Looking for participantsNCT06518564
What this trial is testing

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

Who this might be right for
Endometrial CancerARID1A Gene MutationRecurrent Endometrial Carcinoma
Panagiotis Konstantinopoulos, MD, PhD 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT04953104
What this trial is testing

ARID1A and/or KDM6A Mutation and CXCL13 Expression

Who this might be right for
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma+29 more
M.D. Anderson Cancer Center 6
Early research (Phase 1)WithdrawnNCT04315155
What this trial is testing

Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation

Who this might be right for
Metastatic Adenocarcinoma
University of Utah
Testing effectiveness (Phase 2)Active Not RecruitingNCT04957615
What this trial is testing

Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression

Who this might be right for
Metastatic Malignant Solid NeoplasmUnresectable Solid Neoplasm
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Ended earlyNCT05023655
What this trial is testing

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Who this might be right for
Solid TumorARID1A Gene Mutation
Prisma Health-Upstate 20
Testing effectiveness (Phase 2)Looking for participantsNCT06617923
What this trial is testing

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Who this might be right for
Ovary CancerFallopian Tube CancerPrimary Peritoneal Cavity Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 18
Testing effectiveness (Phase 2)Looking for participantsNCT05490472
What this trial is testing

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Who this might be right for
Solid TumorsER+ Breast CancerTriple Negative Breast Cancer, TNBC+2 more
Jacobio Pharmaceuticals Co., Ltd. 102